Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pediatric Hematology/Oncology
•
BRAF+
•
Langerhans Cell Histiocytosis
Do you recommend using cell-free BRAFV600E to track response to therapy in pediatric patients with langerhans cell histiocytosis?
Related Questions
Do you use prophylactic defibrotide in pediatric patients undergoing BMT who are considered to be at high risk for the development of VOD/SOS?
When do you consider altering treatment for a patient with metastatic osteosarcoma who showed poor response to upfront therapy with MAP (doxorubicin, cisplatin, methotrexate) chemotherapy?
How do you approach anti-seizure medication management when it was started by another team for a seizure-naive patient before/after craniotomy for a tumor?
For patients diagnosed with T-cell lymphoblastic lymphoma with CNS involvement (CSF), what is your approach to the typical schedule for IT chemotherapy?
For patients with Stage IIIB or IV HD flowing Bv-AVEPC with initial large mediastinal adenopathy, how can we avoid ISRT?
For what patients/diagnoses do you currently use sodium thiosulfate to reduce the risk of cisplatin associated ototoxicity?
Can lupus anticoagulant be positive despite a normal aPTT?
What is your approach to screening a cancer survivor for iron overload, and what is your treatment of choice?
What is the optimal timing for PET/CT to assess disease and treatment response with nivo + AVD?
What is your recommended long term management of extensive dural venous sinus thrombosis in an otherwise healthy young patient?
